ORPOF (OSE Immunotherapeutics) Selling, General, & Admin. Expense: $6.49 Mil (TTM As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
51 GF Score
Price $4.43
GF Value $3.33
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Selling, General, & Admin. Expense?

OSE Immunotherapeutics ORPOF 51 Selling, General, & Admin. Expense is $6.49 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 51/100 and a GF Value™ of $3.33 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. OSE Immunotherapeutics's selling, general, & admin. expense for the six months ended in Dec. 2025 was $6.41 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $6.49 Mil.


OSE Immunotherapeutics  (OTCPK:ORPOF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


OSE Immunotherapeutics Selling, General, & Admin. Expense Related Terms


OSE Immunotherapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Selling, General, & Admin. Expense Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.05 0.07 3.50 6.49

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.08 3.42 0.08 6.41

ORPOF vs VRTX, REGN, ALNY: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OSE Immunotherapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Selling, General, & Admin. Expense falls into.


ORPOF
51GF Score
OSE Immunotherapeutics SA ORPOF
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $6.49 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Selling, General, & Admin. Expense of $6.49 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Selling, General, & Admin. Expense too high?
OSE Immunotherapeutics' current Selling, General, & Admin. Expense is $6.49 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Selling, General, & Admin. Expense compare to VRTX and REGN?
OSE Immunotherapeutics' Selling, General, & Admin. Expense of $6.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Selling, General, & Admin. Expense is $6.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.33, compared to a current price of $4.43 — trading 33% above its estimated fair value. The current Selling, General, & Admin. Expense is $6.49 Mil. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Selling, General, & Admin. Expense is $6.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 33% above its estimated GF Value™ of $3.33. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Selling, General, & Admin. Expense: $6.49 Mil
  • GF Value™: $3.33 vs. price of $4.43 (33% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score

Get the complete analysis for ORPOF

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$3.33
GF Value